[3-(1H-benzimidazol-2-yl)-1,1,2,2,3,3-hexachloropropyl]-(trichloromethyl)carbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: [3-(1H-benzimidazol-2-yl)-1,1,2,2,3,3-hexachloropropyl]-(trichloromethyl)carbamic acid
• 化学式: C₁₂H₆Cl₉N₃O₂
• 分子量: 543.3
• InChiKey: DSDFOYWUNQJZGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  69.2
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• TETRAHYDRONAPHTHALENE DERIVATIVES
  申请人：Concert Pharmaceuticals Inc.

  公开号：US20140155444A1

  公开（公告）日：2014-06-05

  This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formulae, in one embodiment: as described herein. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a selective T-type calcium channel blocker.

  本发明涉及新型四氢萘衍生物及其药学上可接受的盐，其化学式如下，在一种实施方式中：如本文所述。本发明还提供包含本发明化合物的组合物，并使用这样的组合物治疗通过给予选择性T型钙通道阻滞剂有益治疗的疾病和病症的方法。
• DEUTERATED TETRAHYDRONAPHTHALENE DERIVATIVES
  申请人：CONCERT PHARMACEUTICALS, INC.

  公开号：EP3144296A1

  公开（公告）日：2017-03-22

  This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formula C, in one embodiment, as described herein. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a selective T-type calcium channel blocker.

  本发明涉及如下式C的新型四氢萘衍生物及其药学上可接受的盐，在一个实施方案中，如本文所述。本发明还提供了包含本发明化合物的组合物，以及这种组合物在治疗通过施用选择性 T 型钙通道阻滞剂而获益的疾病和病症的方法中的用途。
• US9273009B2
  申请人：——

  公开号：US9273009B2

  公开（公告）日：2016-03-01